References
- 1. Loscher W. Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47(8):1253-84.
- 2. Peychev L P. New experimental data in neuropharmacological characteristics of sodium valproate with repeated administration and after withdrawal [dissertation]. Plovdiv: Medicinski Universitet; 1991.
- 3. European Medicines Agency [internet]. London (UK): Trobalt. International Nonproprietary Name: retigabine. Procedure No. EMEA/H/C/001245. c2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/- [cited 2014 Sep 05].
- 4. Splinter MY. Ezogabine (Retigabine) and its role in the treatment of partial-onset seizures: a review. Clin Ther. 2012;34(9):1845-56.
- 5. Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci. 2000;1(1):21-30.
- 6. Akdogan I, Yonguc NG. Experimental Epilepsy Models and Morphologic Alterations of Experimental Epilepsy Models in Brain and Hippocampus. In: Kaneez FS, editor. Underlying Mechanisms of Epilepsy. InTech; 2011. P. 269-82.
- 7. Rostock A, Tober C, Rundtelt C, Bartsch R, Engel J, Polymeropoulos EE, et al. D-23129: a new anticonvulsant with broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 1996;23(3):211-23.
- 8. Sander SE, Lemm C, Lange N et al. Retigabine, a Kv7 (KCNQ) potassium channel opener, attenuates L-DOPA-induce dyskinesias in 6-OHDA-lesioned rats. Neuropharmacology. 2012;62(2):1052-61.
- 9. Blackburn-Munro G, Dalby-Brown W, Mirza NR et al. Retigabine: Chemical Synthesis to Clinical Application. CNS Drug Rev. 2005,11(1):1-20.
- 10. Orhan G, Wuttke TV, Nies AT, Schwab M, Lerche H. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. Expert Opin Pharmacother. 2012;13(12):1807-16.
- 11. Amabile CM, Vasudevan A. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures. Pharmacotherapy. 2013;33(2):187-94.